<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31294" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Warfarin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Shivali</given-names>
          </name>
          <aff>Massachusetts General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Ravneet</given-names>
          </name>
          <aff>Chicago Medical School Rosalind Franklin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Neepa</given-names>
          </name>
          <aff>Hospital of University of Pennsylvania</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivali Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ravneet Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neepa Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31294.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Warfarin is an anticoagulant used to prevent and treat venous thrombosis and thromboembolic events, as well as&#x000a0;conditions such as myocardial infarction,and atrial fibrillation. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, reducing clotting ability. Close monitoring of prothrombin time (PT) and the international normalized ratio (INR) is essential to ensure therapeutic effectiveness and minimize adverse events, such as bleeding. This activity reviews the pharmacokinetics, drug interactions, and adverse event profile of warfarin. Special consideration is given to dose adjustments based on clinical status, diet, genetics, and lifestyle. Contraindications, precautions, and proper administration are discussed to optimize treatment outcomes for patients receiving warfarin.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of warfarin.</p></list-item><list-item><p>Determine FDA-approved indications for warfarin.</p></list-item><list-item><p>Assess contraindications and adverse effects associated with warfarin therapy.</p></list-item><list-item><p>Implement&#x000a0;collaboration and coordination among the interprofessional team to enhance patient care for appropriate dosing and monitoring warfarin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31294&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31294">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31294.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Warfarin is an oral anticoagulant commonly used to treat and prevent blood clots. Warfarin has multiple FDA-approved and off-label clinical uses.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis and treatment of venous thrombosis and arising pulmonary embolism&#x000a0;<xref ref-type="bibr" rid="article-31294.r1">[1]</xref><xref ref-type="bibr" rid="article-31294.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylaxis and treatment of thromboembolic complications from atrial fibrillation or cardiac valve replacement&#x000a0;<xref ref-type="bibr" rid="article-31294.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events after myocardial infarction&#x000a0;<xref ref-type="bibr" rid="article-31294.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Secondary prevention of recurrent stroke and transient ischemic attacks&#x000a0;<xref ref-type="bibr" rid="article-31294.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31294.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Warfarin competitively inhibits the vitamin K epoxide reductase complex subunit 1 (VKORC1), an enzyme essential for activating available vitamin K. Through this mechanism, warfarin can deplete functional vitamin K reserves, thereby reducing the synthesis of active clotting factors. The hepatic synthesis of coagulation factors II, VII, IX, and X, as well as coagulation regulator proteins C and S, requires vitamin K. Vitamin K is an essential cofactor for synthesizing these vitamin K-dependent clotting factors.</p>
        <p>
<bold>Pharmacodynamics</bold>
</p>
        <p><bold>Drug Composition: </bold>Warfarin is a racemic mixture composed of (<italic toggle="yes">R</italic>)- and (<italic toggle="yes">S</italic>)- enantiomers. Each enantiomer&#x000a0;is metabolized through unique pathways, and the (<italic toggle="yes">S</italic>)-enantiomer is 3 to 5 times more potent than the (<italic toggle="yes">R</italic>)- enantiomer.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Warfarin is rapidly and completely absorbed. The onset of action is typically 24 to 72 hours, and the duration of action is&#x000a0;2 to 5 days. Peak plasma concentrations are achieved in approximately 4 hours. A peak therapeutic effect is generally seen 5 to 7 days after initiation. However, the patient's international normalized ratio (INR) may increase within 36 to 72 hours after initiating treatment.</p>
        <p><bold>Distribution:</bold>&#x000a0;Warfarin has a relatively small distribution volume (0.14 L/kg) and undergoes 99% protein binding.</p>
        <p><bold>Metabolism:</bold> Hepatic metabolism, primarily through the CYP2C9 enzyme. Other minor enzymatic pathways for metabolism include CYP2C8, 2C18, 2C19, 1A2, and 3A4.&#x000a0;Research has shown that genetic variations in CYP2C9 affect an individual's warfarin clearance. Patients who are heterozygous for the 2C9 (*1/*2 or *1/*3) experience an approximate 37% reduction in (<italic toggle="yes">S</italic>)- warfarin clearance. Patients who are homozygous for reduced function alleles (*2/*2, *2/*3, or *3/*3) may experience a 70% reduction in clearing(<italic toggle="yes">S</italic>)- warfarin.&#x000a0;The half-life of warfarin is generally 20 to 60 hours; this is highly variable among individuals.</p>
        <p><bold>Elimination:</bold> Warfarin is primarily eliminated as metabolites by glomerular filtration in the kidney (92%).</p>
      </sec>
      <sec id="article-31294.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Warfarin is&#x000a0;available in 1 mg,&#x000a0;2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg, and 10mg oral tablets.</p>
        <p>Warfarin is a once-daily oral medication&#x000a0;that should be administered in the afternoon or evening. By instructing patients to take warfarin later in the day, healthcare providers can have the opportunity to individualize a patient's warfarin dose the same day based on their most current lab values.<xref ref-type="bibr" rid="article-31294.r5">[5]</xref> The dose-response of warfarin among patients is highly variable and depends on interpatient differences. Patient-specific factors such as drug metabolism, the presence of a vitamin K enriched diet, genetics, quantity of vitamin K-dependent clotting factors, concurrent disease states, binding proteins, concomitant drug interactions, laboratory testing, and medication adherence require assessment when dosing warfarin.<xref ref-type="bibr" rid="article-31294.r6">[6]</xref><xref ref-type="bibr" rid="article-31294.r7">[7]</xref></p>
        <p><bold>Adult Dosage</bold>&#x000a0;</p>
        <p>Providers should refer to the most recent evidence-based guidelines from the American College of Chest Physicians (ACCP) to determine appropriate warfarin dosage.<xref ref-type="bibr" rid="article-31294.r8">[8]</xref></p>
        <p><bold>Venous thromboembolism:</bold>&#x000a0;Dosing should be adjusted to achieve and maintain a target INR of 2.5, with an acceptable range of 2.0 to 3.0, for the duration of therapy.</p>
        <p><bold>Atrial fibrillation:</bold> For patients with non-valvular atrial fibrillation (AF), warfarin dosing should be adjusted to maintain an INR of 2.5, ranging from 2.0 to 3.0.</p>
        <p>
<bold>Mechanical and bioprosthetic heart valves:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with a bileaflet mechanical valve or a Medtronic Hall (Minneapolis, MN) tilting disk valve in the aortic position, who are in sinus rhythm and do not have left atrial enlargement, warfarin therapy should target an INR of 2.5.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with tilting disk valves or bileaflet mechanical valves in the mitral position, warfarin therapy should target an INR of 3.0, within a range of 2.5 to 3.5.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with caged ball or caged disk valves, warfarin therapy should also target an INR of 3.0, with a range of 2.5 to 3.5.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with a bioprosthetic mitral valve, warfarin therapy should maintain a target INR of 2.5 (range, 2.0 to 3.0) for the first 3 months post-implantation. If additional thromboembolism risk factors (such as atrial fibrillation, previous thromboembolism, or left ventricular dysfunction) are present, the same INR target of 2.5 (range 2.0 to 3.0) should be maintained.</p>
          </list-item>
        </list>
        <p>
<bold>Post-myocardial infarction:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For high-risk patients&#x000a0;with a history of myocardial infarction (MI) (ie,&#x000a0;large anterior MI, significant heart failure, intracardiac thrombus on transthoracic echocardiography, atrial fibrillation, thromboembolic events), combination therapy with moderate-intensity warfarin (INR range 2.0 to 3.0) and low-dose aspirin (&#x02264;100 mg/day) is recommended for at least 3 months post-MI.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> According to the manufacturer's drug labeling, no dosage adjustments are necessary for patients with liver dysfunction. However,&#x000a0;patients with obstructive jaundice, hepatitis, and cirrhosis&#x000a0;may be more sensitive to oral anticoagulants and require close INR monitoring.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Reduced renal function can cause warfarin to accumulate in the body, increasing bleeding risk. However, dosing adjustments are unnecessary for patients with&#x000a0;kidney&#x000a0;disease; these patients should still be closely monitored. Importantly, warfarin cannot be removed through hemodialysis.<xref ref-type="bibr" rid="article-31294.r9">[9]</xref></p>
        <p><bold>Pregnancy considerations:</bold> Warfarin's pregnancy classification depends on the presence of a mechanical heart valve. Warfarin was listed as a Category D drug for pregnant women with a mechanical heart valve and Category X for all other indications in pregnant women. Warfarin crosses the placental barrier, causing fetal plasma levels similar to maternal values. Warfarin can cause bleeding in the fetus and is associated with spontaneous abortion, stillbirth, preterm birth, and neonatal death. Some experts recommend avoiding warfarin use during the first trimester and close to delivery.<xref ref-type="bibr" rid="article-31294.r10">[10]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Warfarin is not excreted in breast milk, so breastfeeding women may safely receive treatment. However, the manufacturer recommends closely monitoring breastfeeding infants for bruising or bleeding.</p>
        <p><bold>Older patients:</bold>&#x000a0;As the risk of bleeding complications is positively correlated with age, older&#x000a0;adults are at an increased risk of bleeding complications secondary to falls, concomitant drug interactions, cognitive status, and unsafe living conditions. These patients must be monitored closely and may require a more conservative dosage regimen.</p>
        <p><bold>Dietary considerations:</bold> While no specific diet is recommended for patients on warfarin, certain foods and beverages can either suppress&#x000a0;or enhance the anticoagulation effect of warfarin. Vitamin K&#x000a0;reduces the effectiveness of warfarin in the body. Therefore, the patient should receive education on consistent dietary intake of vitamin K-containing foods.<xref ref-type="bibr" rid="article-31294.r11">[11]</xref> Examples of high-vitamin K foods include kale, green tea leaves, brussel sprouts, and spinach. Other dietary recommendations include limiting the consumption of cranberry juice and alcohol while on warfarin therapy. Grapefruit juice and alcohol can enhance the anticoagulant effect of warfarin, thereby leading to increased bleeding complications.<xref ref-type="bibr" rid="article-31294.r12">[12]</xref><xref ref-type="bibr" rid="article-31294.r13">[13]</xref></p>
      </sec>
      <sec id="article-31294.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Severe&#x000a0;adverse effects of warfarin include bleeding and significant hemorrhage. Significant hemorrhage, examples of which include intracranial hemorrhage, gastrointestinal bleeding, hematemesis, intraocular bleeding, and hemarthrosis, can occur at virtually any body site. Patients should receive education about easy bleeding or bruising, a common adverse effect. A clinician should also counsel&#x000a0;patients about properly managing cuts, bruises, and nosebleeds. The risk of bleeding and hemorrhage is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility. Patients should undergo a risk assessment, with appropriate adjustments to their treatment plan made accordingly. Other adverse effects include nausea, vomiting, abdominal pain, bloating, flatulence, and an altered sense of taste.</p>
        <p>There are rare cases of purple toe syndrome and warfarin-induced skin necrosis, in addition to reports of calciphylaxis associated with warfarin therapy.<xref ref-type="bibr" rid="article-31294.r14">[14]</xref><xref ref-type="bibr" rid="article-31294.r15">[15]</xref>&#x000a0;Purple toe syndrome is a complication characterized by cholesterol microembolization that causes purple lesions on the toes and sides of the feet. Purple toe syndrome usually develops 3 to 8 weeks after initiating warfarin therapy. Warfarin-induced skin necrosis is a serious condition in which subcutaneous tissue necrosis occurs due to an acquired protein C deficiency following treatment with warfarin. The risk of necrosis is increased in patients with protein C or protein S deficiency. Calciphylaxis or calcium uremic arteriolopathy is another rare adverse effect in patients with or without end-stage renal disease.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Warfarin has&#x000a0;various known interactions that can increase the risk of adverse effects or&#x000a0;reduce warfarin's anticoagulant effect. Therefore, dosing adjustments, close monitoring, and alternative agents should be considered when combining warfarin with certain medications. Caution is necessary when administering warfarin with the following drug types:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antiplatelet agents</p>
          </list-item>
          <list-item>
            <p>Fibrinolytics</p>
          </list-item>
          <list-item>
            <p>Nonsteroidal anti-inflammatory drugs (NSAIDs)</p>
          </list-item>
          <list-item>
            <p>Antimicrobials</p>
          </list-item>
          <list-item>
            <p>Antiarrhythmic drugs</p>
          </list-item>
          <list-item>
            <p>Other anticoagulants</p>
          </list-item>
        </list>
        <p>The (<italic toggle="yes">S</italic>)- enantiomer of warfarin is 3 to&#x000a0;5 times more potent than the (<italic toggle="yes">R</italic>)- enantiomer. Thus, drug interactions involving the inhibition of the (<italic toggle="yes">S</italic>)-&#x000a0;enantiomer are more significant and may require pre-emptive dose adjustments or therapeutic interchange of alternative anticoagulants. Clinicians should&#x000a0;consult&#x000a0;a comprehensive drug interaction database when necessary.<xref ref-type="bibr" rid="article-31294.r16">[16]</xref></p>
      </sec>
      <sec id="article-31294.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning&#x000a0;</bold>
</p>
        <p>Consistent monitoring of INR levels is essential for all patients receiving warfarin sodium therapy. Various drugs, dietary changes, and other factors can impact the INR&#x000a0;during treatment with warfarin sodium. Clinicians should advise patients on measures to prevent bleeding and instruct them to report any signs or symptoms of bleeding promptly.</p>
        <p>Warfarin is contraindicated in patients with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to warfarin or any component of the formulation&#x000a0;<xref ref-type="bibr" rid="article-31294.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Significant hemorrhage risk
<list list-type="bullet"><list-item><p>active gastrointestinal ulceration&#x000a0;or bleeding</p></list-item><list-item><p>Bleeding from the respiratory or genitourinary tracts</p></list-item><list-item><p>central nervous system (CNS) bleeding</p></list-item><list-item><p>dissecting aortic aneurysm</p></list-item><list-item><p>patients undergoing epidural or spinal puncture or other diagnostic or therapeutic procedures with the potential for significant bleeding&#x000a0;<xref ref-type="bibr" rid="article-31294.r18">[18]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Recent or upcoming&#x000a0;surgery of the eye, central nervous system, or traumatic surgery resulting in large open surfaces</p>
          </list-item>
          <list-item>
            <p>Bleeding associated with pericarditis, pericardial effusion, or bacterial endocarditis</p>
          </list-item>
          <list-item>
            <p>Threatened abortion, preeclampsia, or eclampsia&#x000a0;<xref ref-type="bibr" rid="article-31294.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Unsupervised patients with conditions associated with a high potential of nonadherence to medication</p>
          </list-item>
          <list-item>
            <p>Major regional or lumbar block anesthesia</p>
          </list-item>
          <list-item>
            <p>Malignant hypertension</p>
          </list-item>
          <list-item>
            <p>Pregnancy, except for&#x000a0;patients with mechanical heart valves at an increased risk for thromboembolism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31294.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving treatment with warfarin should&#x000a0;be closely monitored to ensure the safety and efficacy of the medication. Periodic blood testing is recommended to assess the PT and INR.<xref ref-type="bibr" rid="article-31294.r20">[20]</xref></p>
        <p>The laboratory parameter utilized to monitor warfarin therapy is the PT/INR. The PT is the number of seconds required for the blood to clot, and the INR allows for the standardization of the PT measurement depending on the thromboplastin reagent used by a laboratory. Therefore, monitoring the INR while on warfarin is preferable to PT because it allows for a standardized measurement without variations due to different laboratory sites. Routine assessment of INR is essential for patients receiving warfarin therapy. The INR of a healthy patient not on anticoagulation therapy is approximately 1.0.&#x000a0;Therefore, a patient&#x000a0;with an INR of 2.0 or 3.0 requires&#x000a0;2 or&#x000a0;3 times longer for their blood to clot. The therapeutic INR goal for patients on warfarin therapy depends on the indication but may vary based on the patient's clinical presentation and provider preference. Most patients&#x000a0;receiving&#x000a0;warfarin have an INR goal of 2 to 3. However, specific indications, such as a mechanical mitral valve,&#x000a0;may shift the&#x000a0;INR goal to 2.5 to 3.5.<xref ref-type="bibr" rid="article-31294.r21">[21]</xref></p>
        <p>Close INR monitoring is strongly recommended for patients initiating warfarin therapy. This parameter&#x000a0;requires more frequent monitoring&#x000a0;after beginning a warfarin regimen. For hospitalized patients, INR&#x000a0;levels should be obtained daily. Once a patient has reached the maintenance phase of therapy, the INR is typically assessed every 4 weeks. However, this interval is subject to the provider's discretion. More frequent monitoring is necessary for patients with supratherapeutic or subtherapeutic INR to evaluate the safety and efficacy of treatment. Also, the patient's INR requires assessment when initiating, discontinuing, or changing doses of medications known to interact with warfarin.</p>
        <p>Patients also require close monitoring for signs and symptoms of active bleeding throughout their treatment. Close monitoring for signs and symptoms of bleeding, such as dark, tarry stools, nosebleeds, and hematomas, is necessary. The patient's baseline hemoglobin and hematocrit levels should be established before initiating warfarin and reassessed every&#x000a0;6 months while on therapy. Other laboratory tests may be&#x000a0;necessary based on the patient's clinical presentation and INR result, including liver function, renal function, and occult blood&#x000a0;for specific patient populations.<xref ref-type="bibr" rid="article-31294.r22">[22]</xref></p>
      </sec>
      <sec id="article-31294.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Skin necrosis usually occurs within the first week of therapy, and management strategies include discontinuing treatment with warfarin, administering fresh frozen plasma and vitamin K, and initiating anticoagulation therapy with unfractionated heparin (UFH) or low molecular weight heparin (LMWH).</p>
        <p>Warfarin toxicity may be assessed&#x000a0;by observing the signs and symptoms of bleeding, as well as the determination of a supratherapeutic INR level. The risk of bleeding is significantly greater for patients with an elevated INR, especially above 5.0. When managing warfarin toxicity, the initial step would be to discontinue warfarin and then administer vitamin K (phytonadione). Vitamin K&#x000a0;may be administered&#x000a0;orally, intravenously, or subcutaneously. However, the initial administration of oral vitamin K is often preferable&#x000a0;for patients without significant bleeding or elevated INR. A reduction in INR should occur within 24 hours of administration. After that, intravenous vitamin K may be administered if necessary. Due to erratic and unpredictable absorption, subcutaneous vitamin K is often not recommended for warfarin toxicity or reversal. Administering&#x000a0;prothrombin complex concentrate (PCC), fresh frozen plasma (FFP),&#x000a0;or activated Factor VII may be considered for&#x000a0;patients with significant bleeding.<xref ref-type="bibr" rid="article-31294.r2">[2]</xref></p>
      </sec>
      <sec id="article-31294.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All interprofessional healthcare team clinicians, including the primary care provider, advanced-level practitioners, and emergency department physicians, must understand how to manage potential bleeding associated with warfarin. After prescribing warfarin, patients require education about the importance of regular follow-up, foods that interact with warfarin, and when to seek medical help. The prescriber should enlist the services of a pharmacist to help "dial in" the warfarin dose, and inpatients often have their INR and dose adjustments managed by a pharmacist. Nurses must recognize the signs of warfarin toxicity so they can alert the attending or prescribing clinician. Interprofessional team members should also be mindful of other options available today, including the novel oral anticoagulant drugs, which are generally safer and require less intense monitoring. Given the potential severity of warfarin toxicity, healthcare professionals should adopt a collaborative approach to prescribing and managing warfarin. This team should include clinicians, specialists, pharmacists, and nursing staff to maximize therapeutic benefits while minimizing adverse effects.</p>
      </sec>
      <sec id="article-31294.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31294&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31294">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31294/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31294">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31294.s11">
        <title>References</title>
        <ref id="article-31294.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doliner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jaller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lev-Tov</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatments to prevent primary venous ulceration after deep venous thrombosis.</article-title>
            <source>J Vasc Surg Venous Lymphat Disord</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-271.e1</page-range>
            <pub-id pub-id-type="pmid">30660582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Visagan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Issa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gorantla</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18992</fpage>
            <pub-id pub-id-type="pmid">34853735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharp</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>deLaforcade</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Koenigshof</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thomason</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 4-Refining and monitoring antithrombotic therapies.</article-title>
            <source>J Vet Emerg Crit Care (San Antonio)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-87</page-range>
            <pub-id pub-id-type="pmid">30654420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badjatiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <day>12</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">30637536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mckenzie</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wilson-Clarke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prout</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gossell-Williams</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica.</article-title>
            <source>Pharm Pract (Granada)</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>1214</fpage>
            <pub-id pub-id-type="pmid">30637024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Rim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.</article-title>
            <source>Drug Saf</source>
            <year>2019</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>657</fpage>
            <page-range>657-670</page-range>
            <pub-id pub-id-type="pmid">30649749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chokesuwattanaskul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thongprayoon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bathini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Torres-Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Corragain</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Watthanasuntorn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lertjitbanjong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prechawat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kr&#x000f6;ner</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Wijarnpreecha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis.</article-title>
            <source>Dig Liver Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>489</fpage>
            <page-range>489-495</page-range>
            <pub-id pub-id-type="pmid">30594462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gallus</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Wittkowsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Palareti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e44S</fpage>
            <page-range>e44S-e88S</page-range>
            <pub-id pub-id-type="pmid">22315269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garlo</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>DJR</given-names>
              </name>
              <name>
                <surname>Nigwekar</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-136</page-range>
            <pub-id pub-id-type="pmid">30593489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nadeem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khilji</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jalal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Continued use of Warfarin in lower dose has safe maternal and neonatal outcomes in pregnant women with Prosthetic Heart Valves.</article-title>
            <source>Pak J Med Sci</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>933</fpage>
            <page-range>933-938</page-range>
            <pub-id pub-id-type="pmid">34290762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Card</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Kitchen</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Portion-controlled spinach for improved vitamin K antagonist anticoagulant control.</article-title>
            <source>Br J Haematol</source>
            <year>2020</year>
            <month>May</month>
            <volume>189</volume>
            <issue>3</issue>
            <fpage>e71</fpage>
            <page-range>e71-e73</page-range>
            <pub-id pub-id-type="pmid">32017038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>CSS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SWH</given-names>
              </name>
            </person-group>
            <article-title>Warfarin and food, herbal or dietary supplement interactions: A systematic review.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-374</page-range>
            <pub-id pub-id-type="pmid">32478963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Yeh Liu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Kao Yang</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>A practical approach to minimize the interaction of dietary vitamin K with warfarin.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-60</page-range>
            <pub-id pub-id-type="pmid">24383939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pourdeyhimi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bullard</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Warfarin-induced skin necrosis.</article-title>
            <source>Hosp Pharm</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>11</issue>
            <fpage>1044</fpage>
            <page-range>1044-8</page-range>
            <pub-id pub-id-type="pmid">25673894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abutaki</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Alfaraj</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alshahrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elsharkawy</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Warfarin-Induced Calciphylaxis in a COVID-19 Patient.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Dec</month>
            <day>24</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>e12249</fpage>
            <pub-id pub-id-type="pmid">33391959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug interactions induced by Linderane based on mechanism-based inactivation of CYP2C9 and the molecular mechanisms.</article-title>
            <source>Bioorg Chem</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>118</volume>
            <fpage>105478</fpage>
            <pub-id pub-id-type="pmid">34800885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trujillo</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Dobesh</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Crossley</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Finks</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-108</page-range>
            <pub-id pub-id-type="pmid">30548542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilkerson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shepard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Use of Anticoagulation Agents After Traumatic Intracranial Hemorrhage.</article-title>
            <source>World Neurosurg</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>123</volume>
            <fpage>e25</fpage>
            <page-range>e25-e30</page-range>
            <pub-id pub-id-type="pmid">30528524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biasiutti</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Strebel</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>[Anticoagulation and antiaggregation during pregnancy].</article-title>
            <source>Ther Umsch</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-8</page-range>
            <pub-id pub-id-type="pmid">12638480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Role of the anticoagulant monitoring service in 2018: beyond warfarin.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>348</fpage>
            <page-range>348-352</page-range>
            <pub-id pub-id-type="pmid">30504331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bontempi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy.</article-title>
            <source>J Pharmacokinet Pharmacodyn</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-282</page-range>
            <pub-id pub-id-type="pmid">34652608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31294.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>[Study on warfarin medication checklist for improving patient compliance].</article-title>
            <source>Zhonghua Yu Fang Yi Xue Za Zhi</source>
            <year>2021</year>
            <month>Sep</month>
            <day>06</day>
            <volume>55</volume>
            <issue>9</issue>
            <fpage>1133</fpage>
            <page-range>1133-1138</page-range>
            <pub-id pub-id-type="pmid">34619933</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
